A Targeted Treatment for Carbapenem-Resistant <i>Acinetobacter baumannii</i>

The approval of sulbactam-durlobactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections under the FDA fast-track process sets an important precedent for the development of critical antimicrobials for our most resistant organisms. In this monograph, 2 infectious disease specialists review the clinical trial data and early case reports of this important agent, as well as the updated guidance from the Infectious Diseases Society of America.